Effect of simvastatin on plasma homocysteine levels and its modification by mthfr C677T polymorphism in chinese patients with primary hyperlipidemia

Cardiovascular Therapeutics

Volumn 31, Issue 4, 2013, Pages

  Jiang, Shanqun ^a,b   Chen, Qianru ^a   Venners, Scott A ^c   Zhong, Guisheng ^d   Hsu, Yi Hsiang ^e,f   Xing, Houxun ^b   Wang, Xiaobin ^g   Xu, Xiping ^b,h  

^a ANHUI UNIVERSITY   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c SIMON FRASER UNIVERSITY   (Canada)

^d HARVARD UNIVERSITY   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g CHILDREN'S MEMORIAL HOSPITAL   (United States)

^h UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Homocysteine; MTHFR C677T; Polymorphism; Primary hyperlipidemia; Simvastatin

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CREATININE; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL; UREA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINO ACID BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CHINESE; CHOLESTEROL BLOOD LEVEL; CREATININE BLOOD LEVEL; DNA POLYMORPHISM; DRUG EFFECT; FEMALE; GENOTYPE; HEREDITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOCYSTEINE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL;

HOMOCYSTEINE; MTHFR C677T; POLYMORPHISM; PRIMARY HYPERLIPIDEMIA; SIMVASTATIN;

ADMINISTRATION, ORAL; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CHINA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOWN-REGULATION; FEMALE; HOMOCYSTEINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LINEAR MODELS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; SIMVASTATIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84880687112     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12002     Document Type: Article

References (34)

1. Wrone EM, Zehnder JL, Hornberger JM, McCann LM, Coplon NS, Fortmann SP. An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease. Kidney Int 2001;60: 1106-1113.
2. Juskowa J, Bartlomiejczyk J, Paczek L, et al. Total homocysteine as a risk factor for vascular disease in renal transplant recipients. Transplant Proc 2002;34: 576-579.
3. O K, Lynn EG, Chung YH, Siow YL, Man RY, Choy PC. Homocysteine stimulates the production and secretion of cholesterol in hepatic cells. Biochim Biophys Acta 1998;1393: 317-324.
4. Bhandari U, Pathan RA, Kumar V, Khanna N. Ameliorative role of atorvastatin on methionine-induced hyperhomocysteinemia and hematological changes in albino rats. Indian J Exp Biol 2011;49: 132-139.
5. Nigam GK, Ansari MN, Bhandari U. Effect of rosuvastatin on methionine-induced hyperhomocysteinaemia and haematological changes in rats. Basic Clin Pharmacol Toxicol 2008;103: 287-292.
6. Stampfer MJ, Malinow MR, Willet WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in U.S. physicians. J Am Med Assoc 1992;268: 877-881.
7. Anderson JL, Muhlestein JB, Horne BD, Carlquist JF, Bair TL, Madsen TE, Pearson RR. Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation 2000;102: 1227-1232.
8. Qujeq D, Omran TS, Hosini L. Correlation between total homocysteine, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in the serum of patients with myocardial infarction. Clin Biochem 2001;34: 97-101.
9. Davignon J, Laaksonen R. Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol, 1999;10: 543-559.
10. Bao XM, Wu CF, Lu GP. Atorvastatin attenuates homocysteine-induced apoptosis in human umbilical vein endothelial cells via inhibiting NADPH oxidase-related oxidative stress-triggered p38MAPK signaling. Acta Pharmacol Sin 2009;30: 1392-1398.
11. Bao XM, Wu CF, Lu GP. Atorvastatin inhibits homocysteine-induced oxidative stress and apoptosis in endothelial progenitor cells involving Nox4 and p38MAPK. Atherosclerosis 2010;210: 114-121.
12. Xu Z, Lu G, Wu F. Simvastatin suppresses homocysteine-induced apoptosis in endothelial cells: roles of caspase-3, cIAP-1 and cIAP-2. Hypertens Res 2009;32: 375-380.
13. Luftjohann D, Sigit JI, Locatelli S, von Bergmann K. High dose simvastatin (80 mg/day) decreases plasma concentrations of total homocyst(e)ine in patients with hypercholesterolemia. Atherosclerosis 2001;155: 265-266.
14. Vladimirova-Kitova LG, Deneva TI, Marinov B. Effect of moderate and high-dose simvastatin on asymmetric dimethylarginine-homocysteine metabolic pathways in patients with newly detected severe hypercholesterolemia. Cardiovasc Ther 2011;29: 340-348.
15. Kaya C, Cengiz SD, Berker B, Demirtaş S, Cesur M, Erdoǧan G. Comparative effects of atorvastatin and simvastatin on the plasma total homocysteine levels in women with polycystic ovary syndrome: a prospective randomized study. Fertil Steril 2009;92: 635-642.
16. Milionis HJ, Papakostas J, Kakafika A, Chasiotis G, Seferiadis K, Elisaf MS. Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia. J Clin Pharmacol 2003;43: 825-830.
17. MacMahon M, Kirkpatrick C, Cummings CE, Clayton A, Robinson PJ, Tomiak RH, et al. A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). Nutr Metab Cardiovasc Dis 2000;10: 195-203.
18. Giral P, Bruckert E, Jacob N, Chapman MJ, Foglietti M-J, Turpin G. Homocysteine and lipid lowering agents: a comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia. Atherosclerosis 2001;154: 421-427.
19. Malik J, Melenovsky V, Wichterle D, Haas T, Simek J, Ceska R, et al. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial-FAT). Cardiovasc Res 2001;52: 290-298.
20. Melenovsky V, Malik J, Wichterle D, Simek J, Pisarikova A, Skrha J, et al. Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. Am Heart J 2002;144: e6.
21. Sunder-Plassmann G, Fodinger M. Genetic determinants of the homocysteine level. Kidney Int Suppl 2003;84: S141-S144.
22. Girelli D, Friso S, Trabetti E, et al. Methylenetetrahydrofolate reductase C677T mutation, plasma homocysteine, and folate in subjects from northern Italy with or without angiographically documented severe coronary atherosclerotic disease: evidence for an important genetic-environmental interaction. Blood 1998;91: 4158-4163.
23. Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996;93: 7-9.
24. Xu YL, Zhang SC, Li JP, et al. The modification of MTHFR gene polymorphism effect of the correlation between serum folic acid and plasma homocysteine. Acta Universitatis Medicinalis Anhui, 2006;41: 639-642.
25. McNulty H, Pentieva K, Hoey L, Ward M. Homocysteine, B-vitamins and CVD. Proc Nutr Soc, 2008;67: 232-237.
26. Schroecksnadel K, Frick B, Winkler C, Wirleitner B, Weiss G, Fuchs D. Atorvastatin suppresses homocysteine formation in stimulated human peripheral blood mononuclear cells. Clin Chem Lab Med 2005;43: 1373-1376.
27. Elisaf M, Mikhailidis DP. Statins and renal function. Angiology 2002;53: 493-502.
28. Knight SF, Yuan J, Roy S, Imig JD. Simvastatin and tempol protect against endothelial dysfunction and renal injury in a model of obesity and hypertension. Am J Physiol Renal Physiol 2010;298: F86-F94.
29. Jankowski P, Kawecka-Jaszcz K. Lipid-lowering drugs and homocysteine. A comparison between statins and other lipid-lowering drugs. Atherosclerosis 2004;172: 191-194.
30. Maitland-van der Zee AH, Lynch A, Boerwinkle E, et al. Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study. Pharmacogenet Genomics 2008;18: 651-656.
31. Nieminen T, Knuuti J, Hämelahti P, et al. Coronary reactivity, homocysteine and methylenetetrahydrofolate reductase gene variation in young men during pravastatin therapy. Vascul Pharmacol 2007;47: 113-117.
32. Fan FF, Huo Y, Wang X, Xu X, Wang BY, Xu XP, Li JP. Effect of enalapril on plasma homocysteine levels in patients with essential hypertension. J Zhejiang Univ Sci B 2010;11: 583-591.
33. Karatela RA, Sainani GS. Plasma homocysteine in obese, overweight and normal weight hypertensives and normotensives. Indian Heart J 2009;61: 156-159.
34. Human JA, Ubbink JB, Jerling JJ, et al. The effect of Simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolaemia. Clin Chim Acta 1997;263: 67-77.